LUCD vs. AVNS, ZIMV, KIDS, TMCI, CBLL, SMLR, DCTH, BFLY, RXST, and CARL
Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include AVANOS MEDICAL (AVNS), ZimVie (ZIMV), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), CeriBell (CBLL), Semler Scientific (SMLR), Delcath Systems (DCTH), Butterfly Network (BFLY), RxSight (RXST), and Carlsmed (CARL). These companies are all part of the "medical equipment" industry.
Lucid Diagnostics vs. Its Competitors
AVANOS MEDICAL (NYSE:AVNS) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.
In the previous week, Lucid Diagnostics had 9 more articles in the media than AVANOS MEDICAL. MarketBeat recorded 10 mentions for Lucid Diagnostics and 1 mentions for AVANOS MEDICAL. AVANOS MEDICAL's average media sentiment score of 1.18 beat Lucid Diagnostics' score of 0.60 indicating that AVANOS MEDICAL is being referred to more favorably in the media.
95.2% of AVANOS MEDICAL shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 2.6% of AVANOS MEDICAL shares are held by insiders. Comparatively, 6.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
AVANOS MEDICAL has a net margin of -66.89% compared to Lucid Diagnostics' net margin of -1,476.35%. AVANOS MEDICAL's return on equity of 6.16% beat Lucid Diagnostics' return on equity.
Lucid Diagnostics has a consensus price target of $3.65, indicating a potential upside of 254.37%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than AVANOS MEDICAL.
Lucid Diagnostics has lower revenue, but higher earnings than AVANOS MEDICAL. AVANOS MEDICAL is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
AVANOS MEDICAL has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
Summary
Lucid Diagnostics beats AVANOS MEDICAL on 10 of the 16 factors compared between the two stocks.
Get Lucid Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucid Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:LUCD) was last updated on 9/14/2025 by MarketBeat.com Staff
Free LUCD Stock Alerts